First symptoms of Multiple Sclerosis. What age of onset means for treatment and prognosis of multiple sclerosis. 10

First symptoms of Multiple Sclerosis. What age of onset means for treatment and prognosis of multiple sclerosis. 10

First symptoms of Multiple Sclerosis. What age of onset means for treatment and prognosis of multiple sclerosis. 10

Can we help?

More from All
Barrows test
CHF 0.00
Test How to prevent 70% of breast cancers? Tamoxifen. Aromatase inhibitors. 2
CHF 0.00
‘You must give the patient a human touch.’ Top breast cancer expert.
CHF 0.00
Human being can fight so much to stay alive for family and loved ones.
CHF 0.00
We need to learn to share. Doctors of tomorrow will be information managers.
CHF 0.00
Career lessons: 'Learn about disease well and stick to your guns’. Dialysis - early or not? 20
CHF 0.00

Refine your treatment plan with a panel of top doctors who precisely fit your case.

Refine your treatment plan with a panel of top doctors who precisely fit your case.

Refine your treatment plan with a panel of top doctors who precisely fit your case.


Can we help?

Find perfect surgeons or medical specialists to perform your treatment.

Find perfect surgeons or medical specialists to perform your treatment.


Can we help?
Find perfect surgeons or medical specialists to perform your treatment.
Recently viewed Expert Conversations

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Multiple sclerosis commonly presents in young adults. They often have a relapsing-remitting multiple sclerosis course. Dr. Anton Titov, MD. In the majority of patients, multiple sclerosis eventually becomes progressively disabling. It is called secondary progressive multiple sclerosis. Studies of natural history of multiple sclerosis showed that age affects multiple sclerosis progression independent of the disease duration. Dr. Anton Titov, MD. You have done sophisticated MRI analysis of multiple sclerosis cases. Dr. Paul M. Matthews, MD. Multiple sclerosis patients that you studied were similar in everything except the age of the patients. Dr. Anton Titov, MD. What did your clinical trial show? What are its implications for treatment of patients with multiple sclerosis? Dr. Paul M. Matthews, MD. The clinical trial attempted to control for the duration of multiple sclerosis in a group of patients from a common middle age. It showed the following results. Older patients more often had a more aggressive clinical course. It was associated with more profound problems, particularly in the diffuse white matter of the brain. This suggested the greater loss of brain cells and axons. Older patients with multiple sclerosis had more neurodegeneration. This in itself is consistent with long-standing clinical epidemiological data. It has suggested that patients show different rates of progression of multiple sclerosis. Rate of progression depended on the age, at which they first present with multiple sclerosis. Dr. Paul M. Matthews, MD. This clinical trial also highlights the differences in sex ratios between those who present with multiple sclerosis first in mid-life as opposed to early in life. Altogether these factors suggest that there is a strong interaction between the inflammatory processes and the subsequent neurodegeneration. Multiple sclerosis and aging of the brain are likely related to each other. This relates to many other neurodegenerative disorders, in an interesting way. Dr. Paul M. Matthews, MD. Of course, the most common of neurodegenerative disorders is Alzheimer's disease. For all these diseases the single greatest risk connector is, of course, age of a patient. Dr. Anton Titov, MD. There are other predisposing biological factors for neurodegenerative diseases, including multiple sclerosis.